정신 분열병(증)을 SEP-363856, a non–D2-receptor-binding antipsychotic drug으로 치료 한 결과 schizophrenia치료에 좋은 효과가 있다고 한다. Treatment of schizophrenia with SEP-363856, a non–D2-receptor-binding antipsychotic drug, is said to be effective in treating schizophrenia.

정신 분열병(증)을 SEP-363856, a non–D2-receptor-binding antipsychotic drug으로 치료 한 결과 schizophrenia치료에 좋은 효과가 있다고 한다. Treatment of schizophrenia with SEP-363856, a non–D2-receptor-binding antipsychotic drug, is said to be effective in treating schizophrenia.

SEP-363856, a non–D2-receptor-binding antipsychotic drug, resulted in a greater reduction from baseline in the PANSS total score than placebo. Longer and larger trials are necessary to confirm the effects and side effects of SEP-363856, as well as its efficacy relative to existing drug treatments for patients with schizophrenia.

An oral compound, SEP-363856, that does not act on dopamine D2 receptors but has agonist activity at trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT_1A) receptors, may represent a new class of psychotropic agent for the treatment of psychosis in schizophrenia.

소스: Funded by Sunovion Pharmaceuticals; ClinicalTrials.gov num, NEJM 4/16/2020